Lixte Biotechnology Hldgs Inc Financials

LIXT

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

2/9

Lixte Biotechnology Hldgs Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Lixte Biotechnology Hldgs Inc generates $0.88 in operating cash flow (-$3.2M OCF vs -$3.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-212.4x

Lixte Biotechnology Hldgs Inc earns $-212.4 in operating income for every $1 of interest expense (-$3.6M vs $17K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Lixte Biotechnology Hldgs Inc (LIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$3.6M

YoY+29.5%

Lixte Biotechnology Hldgs Inc reported -$3.6M in net income in fiscal year 2024. This represents an increase of 29.5% from the prior year.

EPS (Diluted)

$-1.59

YoY+40.2%

Lixte Biotechnology Hldgs Inc earned $-1.59 per diluted share (EPS) in fiscal year 2024. This represents an increase of 40.2% from the prior year.

Cash & Debt

$1.0M

YoY-75.3%

5Y CAGR-16.8%

10Y CAGR+37.1%

Lixte Biotechnology Hldgs Inc held $1.0M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+0.0%

Lixte Biotechnology Hldgs Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$726K

YoY-19.1%

5Y CAGR-2.4%

10Y CAGR-4.2%

Lixte Biotechnology Hldgs Inc invested $726K in research and development in fiscal year 2024. This represents a decrease of 19.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

LIXT Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$726K-19.1%	$898K-33.4%	$1.3M-22.3%	$1.7M+41.9%	$1.2M+49.1%	$821K
SG&A Expenses	$2.8M-32.1%	$4.2M+64.6%	$2.5M-15.8%	$3.0M+295.3%	$765K-54.2%	$1.7M
Operating Income	-$3.6M+29.8%	-$5.1M+19.3%	-$6.3M+6.1%	-$6.7M-105.7%	-$3.3M-31.2%	-$2.5M
Interest Expense	$17K+3.6%	$16K+82.9%	$9K+19.7%	$7K+101.8%	$4K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.6M+29.5%	-$5.1M+19.4%	-$6.3M+6.2%	-$6.7M-106.1%	-$3.3M-33.8%	-$2.4M
EPS (Diluted)	$-1.59+40.2%	$-2.66+33.3%	$-3.99	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$356K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$51K-16.4%	$61K-33.7%	$91K-74.7%	$362K+71.6%	$211K+77.0%	$119K	N/A	$132K
SG&A Expenses	$1.8M+145.1%	$714K+16.0%	$615K-1.0%	$622K-22.1%	$798K-5.8%	$848K	N/A	$356K
Operating Income	-$1.8M-132.5%	-$775K-9.6%	-$707K+28.1%	-$983K+2.6%	-$1.0M-4.4%	-$967K	N/A	-$1.0M
Interest Expense	$457-74.8%	$2K-42.3%	$3K+198.9%	$1K-74.7%	$4K-42.2%	$7K	N/A	$279
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.0M-155.3%	-$776K-9.3%	-$710K+28.0%	-$986K+2.5%	-$1.0M-4.1%	-$971K	N/A	-$1.0M
EPS (Diluted)	$-0.33-13.8%	$-0.290.0%	$-0.29+34.1%	$-0.44+2.2%	$-0.45-4.7%	$-0.43	N/A	$-0.49

LIXT Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M+95.7%	$2.7M
Current Assets	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M+95.7%	$2.7M
Cash & Equivalents	$1.0M-75.3%	$4.2M-21.5%	$5.4M+11.0%	$4.8M-4.8%	$5.1M+95.1%	$2.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K-9.0%	$238K
Current Liabilities	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K-9.0%	$238K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$827K-79.3%	$4.0M-22.7%	$5.2M+7.8%	$4.8M-4.4%	$5.0M+105.9%	$2.4M
Retained Earnings	-$52.1M-7.4%	-$48.5M-11.7%	-$43.4M-17.0%	-$37.1M-22.2%	-$30.4M-12.1%	-$27.1M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$5.4M+357.2%	$1.2M-21.5%	$1.5M+32.2%	$1.1M-57.1%	$2.7M-25.7%	$3.6M-16.7%	$4.3M-17.7%	$5.2M
Current Assets	$5.4M+449.0%	$990K	N/A	$1.1M-57.1%	$2.7M-25.7%	$3.6M-16.7%	$4.3M-17.7%	$5.2M
Cash & Equivalents	$2.9M+225.5%	$887K-35.9%	$1.4M+33.3%	$1.0M-60.0%	$2.6M-24.0%	$3.4M-18.8%	$4.2M-17.7%	$5.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$521K-2.9%	$537K+51.3%	$355K+11.6%	$318K-24.5%	$421K-8.9%	$463K+47.5%	$314K+0.7%	$312K
Current Liabilities	$521K-2.9%	$537K+51.3%	$355K+11.6%	$318K-24.5%	$421K-8.9%	$463K+47.5%	$314K+0.7%	$312K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.9M+654.0%	$651K-43.8%	$1.2M+40.1%	$827K-63.2%	$2.2M-28.2%	$3.1M-21.7%	$4.0M-18.9%	$4.9M
Retained Earnings	-$55.5M-3.7%	-$53.6M-1.5%	-$52.8M-1.4%	-$52.1M-3.2%	-$50.5M-2.0%	-$49.5M-2.0%	-$48.5M-2.2%	-$47.4M

LIXT Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$3.2M+26.3%	-$4.3M+6.9%	-$4.6M-11.3%	-$4.1M-94.4%	-$2.1M-227.3%	$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$3.1M-38.9%	$5.1M+31.9%	$3.9M-15.3%	$4.6M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$927K-90.1%	-$487K+14.2%	-$568K+5.0%	-$599K+26.9%	-$819K-3.8%	-$789K+12.5%	-$902K+4.5%	-$944K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$5.6M+55747.7%	-$10K-101.1%	$914K	N/A	N/A	N/A	$0-100.0%	$3.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LIXT Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-313.1%-195.0pp	-118.1%-4.6pp	-113.5%+18.6pp	-132.1%-69.7pp	-62.4%+28.9pp	-91.3%
Current Ratio	3.60-10.1	13.73-0.3	14.05-2.8	16.81-7.3	24.15+12.9	11.23
Debt-to-Equity	0.38+0.3	0.080.0	0.08+0.0	0.06+0.0	0.04-0.1	0.10
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-36.4%+28.8pp	-65.3%-18.4pp	-46.9%+11.3pp	-58.1%-20.2pp	-37.9%-10.8pp	-27.1%	N/A	-19.5%
Current Ratio	10.42+8.6	1.84	N/A	3.60-2.7	6.33-1.4	7.75-6.0	13.73-3.1	16.79
Debt-to-Equity	0.11-0.7	0.82+0.5	0.31-0.1	0.38+0.2	0.19+0.0	0.15+0.1	0.08+0.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Akari Therapeutics Plc AKTX

$8.3M

Q32 BIO INC QTTB

$48.0M

BOUNDLESS BIO INC BOLD

$25.3M

Propanc Bio PPCB

$3.2M

Allarity ALLR

$13.6M

Frequently Asked Questions

Is Lixte Biotechnology Hldgs Inc profitable?

No, Lixte Biotechnology Hldgs Inc (LIXT) reported a net income of -$3.6M in fiscal year 2024.

What is Lixte Biotechnology Hldgs Inc's earnings per share (EPS)?

Lixte Biotechnology Hldgs Inc (LIXT) reported diluted earnings per share of $-1.59 for fiscal year 2024. This represents a 40.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Lixte Biotechnology Hldgs Inc's operating cash flow?

Lixte Biotechnology Hldgs Inc (LIXT) generated -$3.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Lixte Biotechnology Hldgs Inc's total assets?

Lixte Biotechnology Hldgs Inc (LIXT) had $1.1M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Lixte Biotechnology Hldgs Inc spend on research and development?

Lixte Biotechnology Hldgs Inc (LIXT) invested $726K in research and development during fiscal year 2024.

How many shares does Lixte Biotechnology Hldgs Inc have outstanding?

Lixte Biotechnology Hldgs Inc (LIXT) had 2M shares outstanding as of fiscal year 2024.

What is Lixte Biotechnology Hldgs Inc's current ratio?

Lixte Biotechnology Hldgs Inc (LIXT) had a current ratio of 3.60 as of fiscal year 2024, which is generally considered healthy.

What is Lixte Biotechnology Hldgs Inc's debt-to-equity ratio?

Lixte Biotechnology Hldgs Inc (LIXT) had a debt-to-equity ratio of 0.38 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lixte Biotechnology Hldgs Inc's return on assets (ROA)?

Lixte Biotechnology Hldgs Inc (LIXT) had a return on assets of -313.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Lixte Biotechnology Hldgs Inc's cash runway?

Based on fiscal year 2024 data, Lixte Biotechnology Hldgs Inc (LIXT) had $1.0M in cash against an annual operating cash burn of $3.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lixte Biotechnology Hldgs Inc's Piotroski F-Score?

Lixte Biotechnology Hldgs Inc (LIXT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lixte Biotechnology Hldgs Inc's earnings high quality?

Lixte Biotechnology Hldgs Inc (LIXT) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lixte Biotechnology Hldgs Inc cover its interest payments?

Lixte Biotechnology Hldgs Inc (LIXT) has an interest coverage ratio of -212.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.